Zila Nutraceuticals, Inc. Offers Customers and Consumers First Vitamin C Soft Chew on Market
PRESCOTT, Ariz. (March 18, 2005) – Zila Nutraceuticals, Inc., maker of Ester-C® and Ester-E®, recently launched its newest product, Ester-C Soft Chew, to customers in the United States and Canada. Ester-C Soft Chew is the first soft chew vitamin C product on the market.
After two years of flavor, texture and taste development, the new form of the vitamin hit shelves for the first time this February. Natrol and Webber Pharmaceutical are the first to market the product, which is currently carried in Longs Drugs, Rite-Aid, Walgreens and Costco Canada.
“With the Ester-C Soft Chew being a first for the vitamin C category, we were committed to bringing a quality, great tasting supplement to consumers on the first try,” said Douglas D. Burkett, Ph.D., Chairman, Chief Executive Officer and President of Zila, Inc. “We manage the entire production of the Soft Chew to ensure the consistent high quality and incredible flavor our customers deserve.”
The 250 mg Ester-C Soft Chew has a sweet, tangy orange flavor and a soft, palatable texture. The vitamin contains 20 calories and is low in carbohydrates. Zila Nutraceuticals plans to introduce additional flavors to its line of soft chews.
“The Soft Chew tastes more like fruit candy than a vitamin, but it offers the same advanced protection as other forms of Ester-C,” said Burkett. “We’re actively pursuing additional innovative delivery forms to keep up with consumer demand.”
The Soft Chew delivery form of Ester-C is designed to meet a variety of needs in the market. The Ester-C Soft Chew is ideal for children, adults with problems swallowing, or those who dislike the often chalky taste and texture of chewable vitamins. An added advantage of the Soft Chew formula is its two-year shelf life.
Visit www.Ester-C.com for more information about the Ester-C Soft Chew and other premium products.
Zila, Inc., headquartered in Phoenix, is an innovator in preventative healthcare technologies and products, focusing on enhanced body defense and the detection of pre-disease states. Zila has three business units:
• Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection through its patented Zila® Tolonium Chloride and OraTest® technologies.
• Zila Pharmaceuticals, marketer of products to promote oral health and prevent oral disease, including ViziLite® oral examination kits, Peridex® prescription periodontal rinse and Zilactin® OTC oral care products.
• Zila Nutraceuticals, manufacturer and marketer of Ester-C® and Ester-E®, branded, highly effective forms of Advanced Protection vitamins C and E.
For more information about Zila, visit www.zila.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2004, and its Form 10-Q for the quarter ended January 31, 2005, filed with the Securities and Exchange Commission.
# # #